3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia.

Journal article

Congenital or hereditary myasthenia describes a heterogeneous group of disorders in which the immune system is not implicated. Treatment has previously depended on anticholinesterase medication. The effectiveness of 3,4-diaminopyridine (3,4-DAP), a preparation that enhances acetylcholine release from motor nerve terminals, has been evaluated using a series of standardised strength measures. Sixteen patients (aged seven to 47 years) were studied in an open prospective trial, and four of them i...

Expand abstract

Authors: Palace, J; Wiles, C; Newsom-Davis, J

• Publication status: Published
• Journal: Journal of neurology, neurosurgery, and psychiatry
• Volume: 54
• Issue: 12
• Pages: 1069-1072
• Publication date: 1991-12-01
• DOI: 10.1136/jnnp.54.12.1069
• EISSN: 1468-330X
• ISSN: 0022-3050
• Language: English
• Keywords: Child; Adolescent; Adult; Electromyography; Prospective Studies; 4-Aminopyridine; Time Factors; Female; Middle Aged; Muscles; Humans; Neuromuscular Diseases; Male